OlukemiAjayi(Ajayi)OlugemoMDFAAN

Neurology • Novato, CA

Neuroimmunology/Multiple Sclerosis

VP, Global Clinical Development, Ultragenyx

Join to view full profile

Dr. Olugemo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Olugemo's full profile

Already have an account?

Office
60 Leveroni Ct
Novato, CA 94949

Education & Training

University of MarylandResidency, Neurology, 2004 - 2007
University of MarylandInternship, Internal Medicine, 2003 - 2004
University of Maryland School of MedicineClass of 2003

Certifications & Licensure

VA State Medical License 2019 - 2026
MD State Medical License 2006 - 2018

Clinical Trials

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) Start of enrollment: 2012 Jul 01
Completed
Phase 1
A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease Start of enrollment: 2013 Jan 01
Terminated
Phase 1
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Approved for marketing
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Start of enrollment: 2022 Jan 04
Recruiting
Phase 3
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Start of enrollment: 2020 Jan 15
Completed
Phase 3
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Start of enrollment: 2020 Mar 13
Active, not recruiting
Phase 3
ATTR Expanded Access Program (EAP) by Ionis
Approved for marketing
TEGSEDI Pregnancy Surveillance Program Start of enrollment: 2020 Jan 15
Recruiting
A Non-interventional Cohort Safety Study of Patients With hATTR-PN Start of enrollment: 2021 Sep 21
Recruiting
Natural History and Functional Status Study of Patients With Lafora Disease Start of enrollment: 2019 Jan 09
Completed
Join now to see all

Press Mentions

Business and governmental leaders come together at first-ever Innovation kNowledge eXchangeJune 18th, 2022
Healthcare Innovation Experts Added to Expanded Speaker Line-Up for Inaugural Innovation kNowledge eXchange of 2022 (INX22)June 18th, 2022
J&J makes a $100 million diversity pledge. Does it go far enough?June 18th, 2022
Join now to see all